Working with the Accelerated Access Collaborative (AAC), the AHSN Network is rolling out FeNO testing to help improve the diagnosis of asthma. Wessex AHSN has produced an extensive online resource area to help NHS organisations implement FeNO testing.
Over 5.4 million people in the UK suffer from asthma. The NHS spends £1.1 billion on asthma treatment and management annually, with 90% of this cost going directly on asthma medication, including the high prescription of steroid inhalers. It’s suspected that 30% of patients currently diagnosed with asthma have been misdiagnosed.
The FeNO test works by measuring fractional exhaled nitric oxide (‘FeNO’) in the breath of patients, and providing a score. Nitric oxide is a biomarker for asthma, which provides an indication of the level of inflammation in the lungs. This can improve patient care and outcomes by:
- More accurate and effective diagnosis of patients suspected of having asthma
- Better understanding of an individual patient’s condition in relation to their FeNO score
- Adjusting doses of steroids or guide biological agents treatment.
FeNO is supported by the Rapid Uptake Products programme 2020/21, which is delivered by the AHSN Network.
Find out more about FeNO in this short film from Jayne Longstaff, Respiratory Quality Improvement Nurse Lead at Portsmouth Hospitals NHS Trust.
Access the FeNO testing implementation toolkit.
For more information, please contact Joe Sladen, Associate Director – National Programmes at Wessex AHSN: firstname.lastname@example.org